Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, open-labeled, controlled, randomized study of recombinant Interleukin-7 (CYT107) treatment to restore and maintain CD4 T-lymphocyte counts above 500 cells/L in HIV-infected patients with CD4 counts remaining between 101-350 cells/mL after at least 2 years of HAART and plasma HIV RNA < 50 copies/mL for 18 months.

Next Previous
Trial Profile

A multicenter, open-labeled, controlled, randomized study of recombinant Interleukin-7 (CYT107) treatment to restore and maintain CD4 T-lymphocyte counts above 500 cells/L in HIV-infected patients with CD4 counts remaining between 101-350 cells/mL after at least 2 years of HAART and plasma HIV RNA < 50 copies/mL for 18 months.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interleukin-7 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms INSPIRE-3

Most Recent Events

  • 07 Feb 2016 Pooled analysis of 2 studies including this INSPIRE 3 trial and other INSPIRE 2 study [see CTP 700052537] were published in the Clinical Infectious Diseases.
  • 24 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
  • 17 Oct 2012 Planned End Date changed from 1 Jul 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top